Clinical Trial Update: A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating safety and therapeutic equivalence of Tazarotene Foam 0.1% in subjects with acne vulgaris has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• Tazarotene Foam 0.1% (tazarotene)

Snippet

Sponsor: Actavis Inc. | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2020-05-11